Reports Q3 revenue $2.23M, consensus $2.91M. "We’re proud of our steady momentum and the external validation of our arenaviral technology over the past few months. Securing our Roche collaboration to develop HB-700 for KRAS-mutated cancers was a key recent achievement, and we’re pleased to move our prostate cancer product candidate, HB-300, toward the clinic following FDA clearance," said CEO Joern Aldag. "With our cash position and upfront cash proceeds from the Roche collaboration, we are positioned to fund multiple clinical readouts in 2023 and 2024, including from our Phase 2 HB-200 program in combination with pembrolizumab."
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on HOOK:
